Literature DB >> 28612201

Supportive care in pancreatic ductal adenocarcinoma.

B Laquente1, A Calsina-Berna2, A Carmona-Bayonas3, P Jiménez-Fonseca4, I Peiró5, A Carrato6.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy. Symptomatic management should be accomplished in a multidisciplinary fashion. Its primary aims include relief of biliary or duodenal obstruction, prevention and/or treatment of thromboembolic disease, and control cancer-related pain. Nutritional support and optimal replacement therapy in patients with endocrine and/or exocrine insufficiency, is mandatory. This manuscript highlights the most significant problems faced when caring for patients with advanced PDAC and provides an evidence-based approach to symptomatic management.

Entities:  

Keywords:  Biliary obstruction; Cachexia; Pancreatic ductal adenocarcinoma; Supportive care; Symptoms; Thromboembolic disease

Mesh:

Year:  2017        PMID: 28612201     DOI: 10.1007/s12094-017-1682-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  60 in total

1.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2017-03       Impact factor: 11.908

Review 2.  Celiac plexus block and neurolysis for pancreatic cancer.

Authors:  Bret M Bahn; Michael A Erdek
Journal:  Curr Pain Headache Rep       Date:  2013-02

3.  Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia.

Authors:  Katie M Di Sebastiano; Lin Yang; Kevin Zbuk; Raimond K Wong; Tom Chow; David Koff; Gerald R Moran; Marina Mourtzakis
Journal:  Br J Nutr       Date:  2012-07-04       Impact factor: 3.718

Review 4.  Celiac plexus block for pancreatic cancer pain in adults.

Authors:  Paolo G Arcidiacono; Giliola Calori; Silvia Carrara; Ewan D McNicol; Pier A Testoni
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 5.  Biomarkers for prediction of venous thromboembolism in cancer.

Authors:  Ingrid Pabinger; Johannes Thaler; Cihan Ay
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

6.  ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.

Authors:  J Arends; G Bodoky; F Bozzetti; K Fearon; M Muscaritoli; G Selga; M A E van Bokhorst-de van der Schueren; M von Meyenfeldt; G Zürcher; R Fietkau; E Aulbert; B Frick; M Holm; M Kneba; H J Mestrom; A Zander
Journal:  Clin Nutr       Date:  2006-05-12       Impact factor: 7.324

7.  Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.

Authors:  Jonathan M Wyse; Marco Carone; Sarto C Paquin; Mariana Usatii; Anand V Sahai
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

8.  Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.

Authors:  Jian-Guo Wang; Julia E Geddings; Maria M Aleman; Jessica C Cardenas; Pichika Chantrathammachart; Julie C Williams; Daniel Kirchhofer; Vladimir Y Bogdanov; Ronald R Bach; Janusz Rak; Frank C Church; Alisa S Wolberg; Rafal Pawlinski; Nigel S Key; Jen Jen Yeh; Nigel Mackman
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

9.  Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.

Authors:  Frederiek F van Doormaal; Marcello Di Nisio; Hans-Martin Otten; Dick J Richel; Martin Prins; Harry R Buller
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

10.  Trousseau's syndrome - what is the evidence? A population-based autopsy study.

Authors:  Mats Ogren; David Bergqvist; Karin Wåhlander; Henry Eriksson; Nils H Sternby
Journal:  Thromb Haemost       Date:  2006-03       Impact factor: 5.249

View more
  8 in total

1.  A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer.

Authors:  Mona Kamal; Xin Shelley Wang; Qiuling Shi; Tito Mendoza; Araceli Garcia-Gonzalez; Raza H Bokhari; Charles S Cleeland; David R Fogelman
Journal:  J Pain Symptom Manage       Date:  2020-01-24       Impact factor: 3.612

2.  [Palliative therapy concepts for pancreatic carcinoma].

Authors:  M Brunner; R Grützmann; G F Weber
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

3.  Palliative care consultation and aggressive care at end of life in unresectable pancreatic cancer.

Authors:  C Lees; S Weerasinghe; N Lamond; T Younis; R Ramjeesingh
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

4.  Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.

Authors:  L Gutierrez-Sainz; D Viñal; J Villamayor; D Martinez-Perez; J A Garcia-Cuesta; I Ghanem; A Custodio; J Feliu
Journal:  Clin Transl Oncol       Date:  2021-04-17       Impact factor: 3.405

Review 5.  Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.

Authors:  Aaron J Grossberg; Linda C Chu; Christopher R Deig; Eliot K Fishman; William L Hwang; Anirban Maitra; Daniel L Marks; Arnav Mehta; Nima Nabavizadeh; Diane M Simeone; Colin D Weekes; Charles R Thomas
Journal:  CA Cancer J Clin       Date:  2020-07-19       Impact factor: 508.702

6.  Altered exocrine function can drive adipose wasting in early pancreatic cancer.

Authors:  Laura V Danai; Ana Babic; Michael H Rosenthal; Emily A Dennstedt; Alexander Muir; Evan C Lien; Jared R Mayers; Karen Tai; Allison N Lau; Paul Jones-Sali; Carla M Prado; Gloria M Petersen; Naoki Takahashi; Motokazu Sugimoto; Jen Jen Yeh; Nicole Lopez; Nabeel Bardeesy; Carlos Fernandez-Del Castillo; Andrew S Liss; Albert C Koong; Justin Bui; Chen Yuan; Marisa W Welch; Lauren K Brais; Matthew H Kulke; Courtney Dennis; Clary B Clish; Brian M Wolpin; Matthew G Vander Heiden
Journal:  Nature       Date:  2018-06-20       Impact factor: 49.962

7.  Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

Authors:  Berta Laquente; Teresa Macarulla; Cristina Bugés; Marta Martín; Carlos García; Carles Pericay; Sandra Merino; Laura Visa; Teresa Martín; Manuela Pedraza; Beatriz Carnero; Raquel Guardeño; Helena Verdaguer; Alejandro Mut; David Vilanova; Adelaida García
Journal:  BMC Palliat Care       Date:  2020-07-10       Impact factor: 3.234

8.  Double Stenting for Malignant Biliary and Duodenal Obstruction: A Systematic Review and Meta-Analysis.

Authors:  Anna Fábián; Renáta Bor; Noémi Gede; Péter Bacsur; Dániel Pécsi; Péter Hegyi; Barbara Tóth; Zsolt Szakács; Áron Vincze; István Ruzsics; Zoltán Rakonczay; Bálint Erőss; Róbert Sepp; Zoltán Szepes
Journal:  Clin Transl Gastroenterol       Date:  2020-04       Impact factor: 4.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.